

**State of Oklahoma  
Oklahoma Health Care Authority  
Daklinza™ (daclatasvir) Initiation Prior Authorization Form**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_  
**Pharmacy NPI:** \_\_\_\_\_ **Pharmacy Phone:** \_\_\_\_\_ **Pharmacy Fax:** \_\_\_\_\_  
**Pharmacy Name:** \_\_\_\_\_ **Pharmacist Name:** \_\_\_\_\_  
**Prescriber NPI:** \_\_\_\_\_ **Prescriber Name:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_  
**Prescriber Phone:** \_\_\_\_\_ **Prescriber Fax:** \_\_\_\_\_ **Drug Name:** \_\_\_\_\_  
**NDC:** \_\_\_\_\_ **Start Date:** \_\_\_\_\_

**Clinical Information**

1. HCV Genotype (including subtype): \_\_\_\_\_ Date Determined: \_\_\_\_\_
  2. METAVIR Equivalent Fibrosis Stage: \_\_\_\_\_ Testing Type: \_\_\_\_\_  
Date Fibrosis Stage Determined: \_\_\_\_\_
  3. Pre-treatment viral load in the last 12 months: \_\_\_\_\_ Date Taken: \_\_\_\_\_  
For METAVIR score of <F1, 2nd test must confirm chronic HCV diagnosis at least 6 months after 1st test.  
Prior pre-treatment viral load or antibody test: \_\_\_\_\_ Date Taken: \_\_\_\_\_
  4. Does member have decompensated hepatic disease (CTP class B or C)? Yes \_\_\_ No \_\_\_
  5. Is the member currently on hospice or does the member have a limited life expectancy (less than 12 months) that cannot be remediated by treating HCV? Yes \_\_\_ No \_\_\_
  6. Has the member been evaluated by a gastroenterologist, infectious disease specialist, or a transplant specialist within the past 3 months? Yes \_\_\_ No \_\_\_
  7. If yes, please include name of specialist recommending hepatitis C treatment: \_\_\_\_\_
  8. Has the member been previously treated for hepatitis C? Yes \_\_\_ No \_\_\_
  9. If yes, please indicate previous treatment regimen and reason for failure (relapser, null-responder, partial responder): \_\_\_\_\_
  10. Please indicate requested regimen below (a separate initiation form must be filled out for Sovaldi®):
    - Daklinza™ 60mg with Sovaldi® x 84 days (12 weeks)
    - Daklinza™ 60mg with Sovaldi® and RBV x 84 days (12 weeks)
    - Concomitant use of a moderate CYP3A inducers: Daklinza™ 90mg with Sovaldi® x 84 days (12 weeks)  
*Moderate Inducers: bosentan, dexamethasone, efavirenz, etravirine, modafinil, nafcillin, and rifapentine*
    - Concomitant use of a strong CYP3A inhibitor: Daklinza™ 30mg with Sovaldi® x 84 days (12 weeks) *Strong Inhibitors: atazanavir/ritonavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, saquinavir, telithromycin, and voriconazole*
    - Other: \_\_\_\_\_
  11. Has the member signed the intent to treat contract\*\*? Yes \_\_\_ No \_\_\_ *\*\*Required for processing of request*
  12. Has the member been counseled on the harms of illicit IV drug use and alcohol use and agreed to not use illicit IV drugs or alcohol while on or after they finish hepatitis C treatment? Yes \_\_\_ No \_\_\_
  13. Has the member initiated immunization with the hepatitis A and B vaccines? Yes \_\_\_ No \_\_\_
  14. For women of childbearing potential (and male patients with female partners of childbearing potential):
    - Patient is not pregnant (or a male with a pregnant female partner) and not planning to become pregnant during treatment
    - Agreement that partners will use two forms of effective non-hormonal contraception during treatment (and for at least 6 months after completing treatment for ribavirin users)  
Please list non-hormonal birth control options discussed with member \_\_\_\_\_
  15. Is the member taking any of the following medications: amiodarone, carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort? Yes \_\_\_ No \_\_\_
  16. Have all other clinically significant issues been addressed prior to starting therapy? Yes \_\_\_ No \_\_\_
- This patient is in need of additional support. I recommend this patient be followed by an OHCA Care Management Nurse.  
**Members must be adherent for continued approval. Treatment gaps of therapy longer than 3 days will result in denial of payment for subsequent requests for continued therapy. Refills must be prior authorized.**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

Has the member been counseled on appropriate use of Daklinza™ therapy? Yes \_\_\_ No \_\_\_

**Pharmacist Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

*Please do not send in chart notes. Specific information/documentation will be requested if necessary. Failure to complete this form in full will result in processing delays. By signature, the prescriber or pharmacist confirms the above information is accurate.*

<p><b>PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:</b>          University of Oklahoma College of Pharmacy          Pharmacy Management Consultants          Product Based Prior Authorization Unit          Fax: 1-800-224-4014          Phone: 1-800-522-0114 Option 4</p>	<p align="center"><b>CONFIDENTIALITY NOTICE</b></p> <p><i>This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.</i></p>
---	---